BioSpace News Archive

CEVEC’s CAP®Go technology enables CellGenix to offer rh TGF-ß1 in preclinical and now also in GMP-grade quality, allowing a seamless transition from preclinical to clinical development and commercial manufacturing of cell therapy products

A comprehensive map of genes necessary for cancer survival is one step closer, following the validation of the two largest CRISPR-Cas9 genetic screens in 725 cancer models, across 25 different cancer types.

Zelluna Immunotherapy announces the appointment of Namir Hassan as chief executive officer.

Dutch life sciences investor Aglaia Oncology Funds, officially launches its ‘Life Sciences Impact Suite’, a groundbreaking tool enabling measurement and reporting of the social impact realized by investments, alongside financial performance.

Sphingotec reports study data demonstrating that its proprietary renal function biomarker penKid(R) (Proenkephalin) predicts acute kidney injury (AKI), multi-organ failure and mortality in sepsis patients presenting to the emergency department (ED).

The Sartorius AI Lab (SAIL) conducts research in the use of artificial intelligence in Sartorius platform solutions for the biopharmaceutical industry

CELLINK’s production is completed in-house without middlemen – this unique advantage enables a workflow with high quality assurance and short lead times.

Cerecin, an innovative biopharmaceutical company focused on brain health, announced that Joseph S. Zakrzewski has joined the Company’s Board of Directors as Chairman.

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to announce that patient screening for its Phase 1 trial to investigate the use in healthy volunteers of delayed release tablets for colonic delivery of oral Brilacidin for treating Ulcerative Colitis,

ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced it has changed the name of the Company to Starton Therapeutics, Inc.